Livzon Pharmaceutical Group Inc is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Zhuhai, Guangdong and currently employs 9,067 full-time employees. Livzon Pharmaceutical Group Inc is a China-based company principally engaged in the research, development, production and sale of pharmaceutical products. The firm's main businesses include chemical drug preparations, biological products, active pharmaceutical ingredients and intermediates, traditional Chinese medicine preparations, diagnostic reagents and equipment, commercial development and functional management. The firm's main products include Ilaprazole (Ilaprazole Enteric-Coated Tablets and Ilaprazole Sodium for Injection), a series of Bismuth Potassium Citrate products, Rabeprazole Sodium Enteric-Coated Capsules, Weisanlian (Bismuth Potassium Citrate Tablets/Tinidazole Tablets/Clarithromycin Tablets), Leuprorelin Acetate Microspheres for Injection, Urofollitropin for Injection, Menotropins for Injection, Voriconazole for Injection and others. The firm mainly operates its businesses in the domestic and overseas markets.
Leveraging in-depth analyst evaluations, we have synthesized key insights from expert assessments to present a positive outlook for LVZPF. Analysts highlight solid fundamentals and favorable market sentiment, suggesting upside potential in the near term. Based on this thorough expert analysis, we maintain an optimistic view of this stock. Our conclusion: LVZPF is a Buy candidate.
LVZPF stock price ended at $5.22 on 木曜日, after rising 52.19%
On the latest trading day Sep 11, 2025, the stock price of LVZPF rose by 52.19%, climbing from $5.22 to $5.22. Throughout the session, the stock experienced a volatility of 0.00%, with prices fluctuating between a daily low of $5.22 and a high of $5.22. Alongside this price increase, trading volume also rose by 1.0K shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 100 shares were traded, amounting to a market value of approximately $1.5B.